Long-term proton pump inhibitor use and gastrointestinal cancer

Current Gastroenterology Reports

Volumn 10, Issue 6, 2008, Pages 543-547

  Graham, David Y ^a   Genta, Robert M ^b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ATROPHY; CANCER RISK; DIGESTIVE SYSTEM CANCER; DRUG CARCINOGENICITY; DRUG EFFICACY; DRUG SAFETY; ENTEROCHROMAFFIN CELL; ERADICATION THERAPY; GASTRITIS; GASTROINTESTINAL SYMPTOM; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HYPERGASTRINEMIA; HYPERPLASIA; LONG TERM CARE; MALIGNANT TRANSFORMATION; NONHUMAN; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; STOMACH CARCINOID; STOMACH MUCOSA; STOMACH POLYP;

ANIMALS; ATROPHY; GASTRIC ACID; GASTRIC MUCOSA; GASTRINS; GASTROINTESTINAL NEOPLASMS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PRECANCEROUS CONDITIONS; PROTON PUMP INHIBITORS;

EID: 60749113725     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-008-0100-1     Document Type: Review

References (42)

1. Yeomans ND, Brimblecombe RW, Elder J, et al.: Effects of acid suppression on microbial flora of upper gut. Dig Dis Sci 1995, 40: 81S-95S.
2. Correa P: Chronic gastritis as a cancer precursor. Scand J Gastroenterol Suppl 1984, 104: 131-136.
3. Graham DY, Sung JY: Helicobacter pylori. In Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. edn 7. Edited by Feldman M, Friedman LS, Brandt LJ. Philadelphia: WB Saunders Co; 2006:1049-1066.
4. Elster K: Histologic classification of gastric polyps. Curr Top Pathol 1976, 63: 77-93.
5. Jalving M, Koornstra JJ, Gotz JM, et al.: High-grade dysplasia in sporadic fundic gland polyps: A case report and review of the literature. Eur J Gastroenterol Hepatol 2003, 15: 1229-1233.
6. Jalving M, Koornstra JJ, Wesseling J, et al.: Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther 2006, 24: 1341-1348.
7. Choudhry U, Boyce HW Jr, Coppola D: Proton pump inhibitor-associated gastric polyps: A retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics. Am J Clin Pathol 1998, 110: 615-621.
8. Kazantsev GB, Schwesinger WH, Heim-Hall J: Spontaneous resolution of multiple fundic gland polyps after cessation of treatment with lansoprazole and Nissen fundoplication: A case report. Gastrointest Endosc 2002, 55: 600-602.
9. Stolte M: FundiA gland polyps: a rare, innocuous, and reversible disturbance. Gastroenterology 1993, 105: 1590-1591.
10. Orlando LA, Lenard LC Orlando RC: Chronic hypergastrinemia: causes and consequences. Dig Dis Sci 2007, 52: 2482-2489.
11. Unge P, Gad A, Gnarpe H, Olsson J: Does omeprazole improve antimicrobial therapy directed towards gastric Campylobacter pylori in patients with antral gastritis? A pilot study. Scand J Gastroenterol Suppl 1989, 167: 49-54.
12. Stolte M, Bethke B: Elimination of Helicobacter pylori under treatment with omeprazole. Z Gastroenterol 1990, 28: 271-274.
13. Graham DY, Opekun AR, Yamaoka Y, et al.: Early events in proton pump inhibitor-associated exacerbation of corpus gastritis. Aliment Pharmacol Ther 2003, 17: 193-200.
14. Scott D, Weeks D, Melchers K, Sachs G: The life and death of Helicobacter pylori. Gut 1998, 43(Suppl 1): S56-S60.
15. Kuipers EJ, Lee A, Klinkenberg-Knol EC, Meuwissen SG: Review article: the development of atrophic gastritis - Helicobacter pylori and the effects of acid suppressive therapy. Aliment Pharmacol Ther 1995, 9: 331-340.
16. Kuipers EJ, Uyterlinde AM, Pena AS, et al.: Long-term sequelae of Helicobacter pylori gastritis. Lancet 1995, 345: 1525-1528.
17. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al.: Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996, 334: 1018-1022.
18. Kuipers EJ, Klinkenberg-Knol EC, Vandenbroucke-Grauls CM, et al.: Role of Helicobacter pylori in the pathogenesis of atrophic gastritis. Scand J Gastroenterol Suppl 1997, 223: 28-34.
19. Moayyedi P, Wason C, Peacock R, et al.: Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter 2000, 5: 206-214.
20. Lundell L, Havu N, Miettinen P, et al.: Changes of gastric mucosal architecture during long-term omeprazole therapy: Results of a randomized clinical trial. Aliment Pharmacol Ther 2006, 23: 639-647.
21. Larkin CJ, Watson RGP, Sloan JM, et al.: Distribution of atrophy in Helicobacter pylori-infected subjects taking proton pump inhibitors. Scand J Gastroenterol 2000, 35: 578-582.
22. Eissele R, Brunner G, Simon B, et al.: Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997, 112: 707-717.
23. Schenk BE, Kuipers EJ, Nelis GF, et al.: Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut 2000, 46: 615-621.
24. Bateson MC: Hypergastrinaemia with long-term omeprazole treatment. Aliment Pharmacol Ther 1999, 13: 440-441.
25. Ligumsky M, Lysy J, Siguencia G, Friedlander Y: Effect of long-term, continuous versus alternate-day omeprazole therapy on serum gastrin in patients treated for reflux esophagitis. J Clin Gastroenterol 2001, 33: 32-35.
26. Robinson MC Review article: current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperplasia. Aliment Pharmacol Ther 1999, 13(Suppl 5): 5-10.
27. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al.: Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol 1999, 94: 884-887.
28. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al.: Hypergastrinaemia during long-term omeprazole therapy: Influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. Aliment Pharmacol Ther 1998, 12: 605-612.
29. Lamberts R, Brunner G, Solcia E: Effects of very long (up to 1 0 years) proton pump blockade on human gastric mucosa. Digestion 2001, 64: 205-213.
30. Genta RM, Rindi G, Fiocca R, et al.: Effects of 6-12 months of esomeprazole treatment on the gastric mucosa. Am J Gastroenterol 2003, 98: 1257-1265.
31. Robertson DJ, Larsson H, Friis S, et al.: Proton pump inhibitor use and risk of colorectal cancer: A population-based, casecontrol study. Gastroenterology 2007, 133: 755-760.
32. Yang YX, Hennessy S, Propert K, et al.: Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology 2007, 133: 748-754.
33. Graham DY, Uemura N: Natural history of gastric cancer after Helicobacter pylori eradication in Japan: After endoscopic resection, after treatment of the general population, and naturally. Helicobacter 2006, 11: 139-143.
34. Valuck RJ, Ruscin JM: A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 2004, 57: 422-428.
35. Cunningham R, Dale B, Undy B, Gaunt N: Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003, 54: 243-245.
36. Hauben M, Horn S, Reich L, Younus M: Association between gastric acid suppressants and Clostridium difficile colitis and community-acquired pneumonia: Analysis using pharmacovigilance tools. Int J Infect Dis 2007, 11: 417-422.
37. Cadle RM, Mansouri MD, Logan N, et al.: Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health Syst Pharm 2007, 64: 2359-2363.
38. Vestergaard P, Rejnmark L, Mosekilde L: Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006, 79: 76-83.
39. Mallow S, Rebuck JA, Osler T, et al.: Do proton pump inhibitors increase the incidence of nosocomial pneumonia and related infectious complications when compared with histamine-2 receptor antagonists in critically ill trauma patients? Curr Surg 2004, 61: 452-458.
40. Yang YX, Lewis JD, Epstein S, Metz DC: Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006, 296: 2947-2953.
41. Graham DY, Chan FK: NSAIDs, risks, and gastroprotective strategies: current status and future. Gastroenterology 2008, 134: 1240-1246.
42. Raghunath TS, O'Morain C, McLoughlin RC: Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther 2005, 22(Suppl 1): 55-63.